Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...

Linda Hoffman-Pugh, a former housekeeper for JonBenét Ramsey‘s family, has died at the age of 82. Hoffman-Pugh was working for the family when JonBenét was tragically murdered at just 6 years old on ...

Patsy Kensit will return to Emmerdale after two decades to reprise her role as Sadie King. The actress played the villainous character on the ITV soap for a two-year stint between 2004 and 2006. She ...

Emmerdale has confirmed the return of Patsy Kensit as Sadie King. It was recently reported that the star, who appeared on EastEnders a few years ago, would be back as the villainous character after 20 ...

You don’t mess with the classics. In a chaotic world that ceaselessly hurls distractions at us through the digital rectangular devices in our pockets, it’s often the slow, frill-less, anachronistic ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels continue their conversation on communicating ...

Eli Lilly has chalked up another victory in the chronic lymphocytic leukemia (CLL) space, as its BTK inhibitor Jaypirca delivered its fourth positive phase 3 readout in the blood cancer. Monday, Lilly ...

Virginia native and noted country music artist Patsy Cline died in a plane crash in Tennessee. Cline is buried at Shenandoah Memorial Park in Winchester. Gray Media, parent company of WDBJ7, is ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Patsy Cline is an undisputed country queen. Her legacy is well felt throughout Music City. There isn’t a country artist around today that can’t credit some of their sound to Cline’s era-defining run ...

Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free survival. Median progression-free survival was 9.5 years from initial treatment ...